**GI Esophageal / Gastric**

- **Localized**
  - **1st Line**
  - **2nd Line**
  - No Trials Currently Available

- **HER 2+**
  - 1st Line
  - 2nd Line
  - IRB# 18147
  - A Phase 3, Double-blind, Randomized Study of BGB-290 versus Placebo as Maintenance Therapy in Patients with Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based First-line Chemotherapy

- **HER 2-**
  - 1st Line
  - 2nd Line
  - IRB# 18340
  - A Phase 3, Global, Multicenter, Double-blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ)

- **Metastatic**
  - IRB# 18147
  - A Phase 3, Double-blind, Randomized Study of BGB-290 versus Placebo as Maintenance Therapy in Patients with Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based First-line Chemotherapy

**Adjuvant**

- IRB# 16058
  - A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer (CheckMate 577; CHECKpoint pathway and nivolumab clinical trial evaluation 577)

**Cross-Disease Trials:**

- IRB# TBD
  - EAY131 (MATCH)

**Key:**
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php